Abstract
5-hydroxymethylcytosine (5hmC) is a modified base present at low levels in diverse cell types in mammals1,2,3,4,5. 5hmC is generated by the TET family of Fe(II) and 2-oxoglutarate-dependent enzymes through oxidation of 5-methylcytosine (5mC)1,2,4,5,6,7. 5hmC and TET proteins have been implicated in stem cell biology and cancer1,4,5,8,9, but information on the genome-wide distribution of 5hmC is limited. Here we describe two novel and specific approaches to profile the genomic localization of 5hmC. The first approach, termed GLIB (glucosylation, periodate oxidation, biotinylation) uses a combination of enzymatic and chemical steps to isolate DNA fragments containing as few as a single 5hmC. The second approach involves conversion of 5hmC to cytosine 5-methylenesulphonate (CMS) by treatment of genomic DNA with sodium bisulphite, followed by immunoprecipitation of CMS-containing DNA with a specific antiserum to CMS5. High-throughput sequencing of 5hmC-containing DNA from mouse embryonic stem (ES) cells showed strong enrichment within exons and near transcriptional start sites. 5hmC was especially enriched at the start sites of genes whose promoters bear dual histone 3 lysine 27 trimethylation (H3K27me3) and histone 3 lysine 4 trimethylation (H3K4me3) marks. Our results indicate that 5hmC has a probable role in transcriptional regulation, and suggest a model in which 5hmC contributes to the ‘poised’ chromatin signature found at developmentally-regulated genes in ES cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009)
Kriaucionis, S. & Heintz, N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324, 929–930 (2009)
Szwagierczak, A., Bultmann, S., Schmidt, C. S., Spada, F. & Leonhardt, H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. 38, e181 (2010)
Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129–1133 (2010)
Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 . Nature 468, 839–843 (2010)
Iyer, L. M., Tahiliani, M., Rao, A. & Aravind, L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8, 1698–1710 (2009)
Loenarz, C. & Schofield, C. J. Oxygenase catalyzed 5-methylcytosine hydroxylation. Chem. Biol. 16, 580–583 (2009)
Koh, K. P. et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 8, 200–213 (2011)
Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009)
Zhang, H., Li, X. J., Martin, D. B. & Aebersold, R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nature Biotechnol. 21, 660–666 (2003)
Song, C. X. et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nature Biotechnol. 29, 68–72 (2011)
Hayatsu, H. & Shiragami, M. Reaction of bisulfite with the 5-hydroxymethyl group in pyrimidines and in phage DNAs. Biochemistry 18, 632–637 (1979)
Huang, Y. et al. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS ONE 5, e8888 (2010)
Harris, T. D. et al. Single-molecule DNA sequencing of a viral genome. Science 320, 106–109 (2008)
Bowers, J. et al. Virtual terminator nucleotides for next-generation DNA sequencing. Nature Methods 6, 593–595 (2009)
Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315–322 (2009)
Saxonov, S., Berg, P. & Brutlag, D. L. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl Acad. Sci. USA 103, 1412–1417 (2006)
Feng, S. et al. Conservation and divergence of methylation patterning in plants and animals. Proc. Natl Acad. Sci. USA 107, 8689–8694 (2010)
Creyghton, M. P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA 10.1073/pnas.1016071107 (24 November 2010)
Boyer, L. A. et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349–353 (2006)
Guttman, M. et al. Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nature Biotechnol. 28, 503–510 (2010)
Mikkelsen, T. S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553–560 (2007)
Ku, M. et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. 4, e1000242 (2008)
Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766–770 (2008)
Zhang, H. et al. TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res. 20, 1390–1393 (2010)
Lee, T. I. et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125, 301–313 (2006)
Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326 (2006)
Fouse, S. D. et al. Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell 2, 160–169 (2008)
Acknowledgements
We thank B. Ren for assistance in next generation sequencing using the Illumina platform. We thank M. Guttman for making his RNASeq data set available to us. W.A.P. is supported by a predoctoral graduate research fellowship from the National Science Foundation, and Y.H. by a postdoctoral fellowship from the Leukemia and Lymphoma Society. R.L. is supported by a California Institute for Regenerative Medicine Training Grant. This study was supported by the National Institute of Health grants RC1 DA028422, R01 AI44432 and 1 R01 HD065812-01A1 and a grant from the California Institute of Regenerative Medicine (to A.R.), a pilot grant from Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH Grant 1 UL1 RR 025758-02) and NIH K08 HL089150 (to S.A.), and a grant from the Mary. K. Chapman Foundation (to J.R.E.).
Author information
Authors and Affiliations
Contributions
W.A.P., Y.B. and S.A. devised the GLIB method. W.A.P., S.A., H.R.H. and E.M.M. optimized the GLIB method. Y.H. generated the anti-CMS antiserum, and Y.H. and W.A.P. optimized the anti-CMS pull-down. W.A.P. and Y.H. grew ES cells. W.A.P. prepared GLIB samples for sequencing, Y.H. prepared CMS samples, H.R.H. performed MeDIPs. Helicos sequencing and mapping was performed by P.K. and P.M.M., Illumina sequencing and mapping was performed by R.L. and J.R.E., and U.J.P. was responsible for bioinformatic analysis. M.K. performed the anti-5hmC dot blot. W.A.P. and M.T. performed anti-5hmC pull-downs. H.R.H. and S.M. performed and optimized in vitro tests of Tet substrate specificity. W.A.P., S.A. and A.R. wrote the manuscript. S.A. and A.R. coordinated research.
Corresponding authors
Ethics declarations
Competing interests
P.K. and P.M.M. are employees of Helicos Biosciences.
Supplementary information
nature10102-s1.pdf Supplementary Information
This file contains Supplementary Figures 1-5 with legends, Supplementary Methods, additional references and Supplementary Tables 1-3 (PDF 1197 kb)
Supplementary Table 4. GLIB Peak Annotation.
This table shows the location of every GLIB HERG and the genomic features it is enclosed within (or in the case of exons, transcription start sites, or enhancers, touches). (XLS 22370 kb)
Supplementary Table 5. GLIB Peak Locations.
This table shows the location of each GLIB HERG in the Mus Musculus (mm9) genome. (TXT 5055 kb)
Supplementary Table 6. CMS Peak Annotation.
This table shows the location of every CMS HERG and the genomic features it is enclosed within (or in the case of exons, transcription start sites, or enhancers, touches). (XLS 23176 kb)
Supplementary Table 7. CMS Peak Locations.
This table shows the location of each CMS HERG in the Mus Musculus (mm9) genome. (TXT 4601 kb)
Supplementary Table 8. 5mC Peak Annotation.
This table shows the location of every MERG and the genomic features it is enclosed within (or in the case of exons, transcription start sites, or enhancers, touches). (XLS 21412 kb)
Supplementary Table 9. 5mC Peak Locations.
This table shows the location of each MERG in the Mus Musculus (mm9) genome. (TXT 2648 kb)
Supplementary Table 9. Visualization of hoxb locus
This file shows reads from the GLIB (reads.glib.hmc) and anti-CMS (reads.cms.hmc) precipitations. Also shown are the reads from the –BGT control (reads.glib.bg), the bisulphite treated input (reads.cms.bg), and the HERGs from each method (peaks.glib and peaks.cms). (TXT 3101 kb)
Supplementary Table 11. List of hydroxymethylated TSS genes (by GLIB).
This table lists every gene that overlaps with a HERG (as determined by GLIB) at or immediately prior to the TSS (-800bp to +200bp). Featured is the RefSeq output, the promoter CpG class and histone methylation state22, the expresson decile in ES cells21, the presence or absence of polycomb features at the promoter23, change in expression upon differentiation to embryoid bodies20, and upregulation or downregulation in response to Tet1 depletion8. (XLS 4771 kb)
Supplementary Table 12. List of hydroxymethylated TSS genes (by anti-CMS).
This table lists every gene that overlaps with a HERG (as determined by anti-CMS precipitation) at or immediately prior to the TSS (-800bp to +200bp). Featured is the RefSeq output, the promoter CpG class and histone methylation state22, the expresson decile in ES cells21, the presence or absence of polycomb features at the promoter23, change in expression upon differentiation to embryoid bodies20, and upregulation or downregulation in response to Tet1 depletion8. (XLS 4291 kb)
Supplementary Table 13. List of methylated TSS genes (by MeDIP).
This table lists every gene that overlaps with a MERG at or immediately prior to the TSS (-800bp to +200bp). Featured is the RefSeq output, the promoter CpG class and histone methylation state22, the expresson decile in ES cells21, the presence or absence of polycomb features at the promoter23, the change in expression upon differentiation to embryoid bodies20, and upregulation or downregulation in response to Tet1 depletion8. (XLS 644 kb)
Rights and permissions
About this article
Cite this article
Pastor, W., Pape, U., Huang, Y. et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473, 394–397 (2011). https://doi.org/10.1038/nature10102
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature10102
This article is cited by
-
Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis
Cell Death & Disease (2023)
-
Analysis of archaic human haplotypes suggests that 5hmC acts as an epigenetic guide for NCO recombination
BMC Biology (2022)
-
Aberrant DNA hydroxymethylation reshapes transcription factor binding in myeloid neoplasms
Clinical Epigenetics (2022)
-
Whole-genome profiling of DNA methylation and hydroxymethylation identifies distinct regulatory programs among innate lymphocytes
Nature Immunology (2022)
-
Tet Enzymes-Mediated DNA 5hmC Modification in Cerebral Ischemic and Hemorrhagic Injury
Neurotoxicity Research (2022)